PL3846801T3 - Zastosowanie modulatorów cftr do leczenia stanów mózgowo-naczyniowych - Google Patents
Zastosowanie modulatorów cftr do leczenia stanów mózgowo-naczyniowychInfo
- Publication number
- PL3846801T3 PL3846801T3 PL19762831.6T PL19762831T PL3846801T3 PL 3846801 T3 PL3846801 T3 PL 3846801T3 PL 19762831 T PL19762831 T PL 19762831T PL 3846801 T3 PL3846801 T3 PL 3846801T3
- Authority
- PL
- Poland
- Prior art keywords
- cftr modulators
- treating cerebrovascular
- cerebrovascular conditions
- conditions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18193319 | 2018-09-09 | ||
| PCT/EP2019/074011 WO2020049189A1 (en) | 2018-09-09 | 2019-09-09 | Use of cftr modulators for treating cerebrovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3846801T3 true PL3846801T3 (pl) | 2025-07-14 |
Family
ID=63556150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19762831.6T PL3846801T3 (pl) | 2018-09-09 | 2019-09-09 | Zastosowanie modulatorów cftr do leczenia stanów mózgowo-naczyniowych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210346359A1 (pl) |
| EP (1) | EP3846801B1 (pl) |
| JP (1) | JP7560011B2 (pl) |
| KR (1) | KR102857176B1 (pl) |
| CN (1) | CN113316450B (pl) |
| AU (1) | AU2019334684B2 (pl) |
| CL (1) | CL2021000579A1 (pl) |
| ES (1) | ES3028365T3 (pl) |
| MX (1) | MX2021002653A (pl) |
| PL (1) | PL3846801T3 (pl) |
| UA (1) | UA129188C2 (pl) |
| WO (1) | WO2020049189A1 (pl) |
| ZA (1) | ZA202102271B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4245302A1 (en) | 2022-03-15 | 2023-09-20 | Charité - Universitätsmedizin Berlin | Cftr modulators for the treatment of vascular disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759335B2 (en) | 2004-01-30 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005107730A2 (en) * | 2004-05-03 | 2005-11-17 | Omega Bio-Pharma (I.P.3) Limited | Cysteamines for treating complications of hypercholesterolemia and diabetes |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2009004702A (es) | 2006-11-03 | 2009-06-19 | Vertex Pharma | Derivados de azaindol como moduladores del regulador de conductancia de transmembrana de fibrosis quistica. |
| NZ703814A (en) | 2008-02-28 | 2016-06-24 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| SI2615085T1 (sl) | 2008-03-31 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Piridilni derivati kot cftr-modulatorji |
| WO2010040862A2 (en) | 2008-12-12 | 2010-04-15 | Universitätsklinikum Münster | New activators for treating and/or preventing diseases or medical conditions which benefit from an increased transport of hyaluronan across a lipid bilayer |
| US8513242B2 (en) * | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| WO2012166654A1 (en) | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
| ITMI20111068A1 (it) | 2011-06-14 | 2012-12-15 | Azienda Ospedaliera Universitaria I Ntegrata Di Ve | Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale |
| ES2656321T3 (es) | 2012-05-17 | 2018-02-26 | I.E.R.F.C. European Institute For Cystic Fibrosis Research | Terapia combinada para fibrosis quística |
| US9676779B2 (en) | 2012-11-20 | 2017-06-13 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| WO2014081821A2 (en) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small Molecule Bicyclic and Tricyclic CFTR Correctors |
| JP6514680B2 (ja) | 2013-03-15 | 2019-05-15 | ディスカバリーバイオメッド， インコーポレイテッド | クマリン誘導体、ならびに嚢胞性線維症、慢性閉塞性肺疾患、及びミスフォールドタンパク質障害の治療における使用方法 |
| CA2971855A1 (en) * | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
-
2019
- 2019-09-09 PL PL19762831.6T patent/PL3846801T3/pl unknown
- 2019-09-09 EP EP19762831.6A patent/EP3846801B1/en active Active
- 2019-09-09 ES ES19762831T patent/ES3028365T3/es active Active
- 2019-09-09 CN CN201980068691.XA patent/CN113316450B/zh active Active
- 2019-09-09 JP JP2021537500A patent/JP7560011B2/ja active Active
- 2019-09-09 MX MX2021002653A patent/MX2021002653A/es unknown
- 2019-09-09 UA UAA202101859A patent/UA129188C2/uk unknown
- 2019-09-09 AU AU2019334684A patent/AU2019334684B2/en active Active
- 2019-09-09 US US17/274,726 patent/US20210346359A1/en active Pending
- 2019-09-09 WO PCT/EP2019/074011 patent/WO2020049189A1/en not_active Ceased
- 2019-09-09 KR KR1020217010066A patent/KR102857176B1/ko active Active
-
2021
- 2021-03-09 CL CL2021000579A patent/CL2021000579A1/es unknown
- 2021-04-06 ZA ZA2021/02271A patent/ZA202102271B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7560011B2 (ja) | 2024-10-02 |
| UA129188C2 (uk) | 2025-02-05 |
| EP3846801A1 (en) | 2021-07-14 |
| MX2021002653A (es) | 2021-09-23 |
| KR20210088532A (ko) | 2021-07-14 |
| JP2022500492A (ja) | 2022-01-04 |
| CN113316450A (zh) | 2021-08-27 |
| EP3846801B1 (en) | 2025-03-12 |
| WO2020049189A1 (en) | 2020-03-12 |
| CL2021000579A1 (es) | 2022-04-18 |
| AU2019334684B2 (en) | 2025-03-06 |
| AU2019334684A1 (en) | 2021-05-13 |
| KR102857176B1 (ko) | 2025-09-08 |
| EP3846801C0 (en) | 2025-03-12 |
| ES3028365T3 (en) | 2025-06-19 |
| CN113316450B (zh) | 2024-05-24 |
| US20210346359A1 (en) | 2021-11-11 |
| ZA202102271B (en) | 2022-07-27 |
| CA3111843A1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275482A (en) | Asketamine for the treatment of depression | |
| EP3509584A4 (en) | Glucocorticoid receptor modulators to treat pancreatic cancer | |
| IL259421B (en) | ror - gamma modulators | |
| PL3376954T3 (pl) | Aparat do leczenia zaburzeń neurologicznych układu słuchowego | |
| IL283672A (en) | trex1 modulators | |
| SG11202106378VA (en) | Modulators of hsd17b13 expression | |
| SG11202102636UA (en) | Modulators of pnpla3 expression | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL265342A (en) | Use of pridofidine for the treatment of Rett syndrome | |
| IL262825A (en) | Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment | |
| IL260775B (en) | Using gabaa receptor modulators to treat itching | |
| IL283948A (en) | Methods for treating depression | |
| SG11202003453QA (en) | Method of treating acid-base disorders | |
| GB201709403D0 (en) | Compounds for treating sarcoma | |
| IL266180A (en) | Materials and methods for the control of biofilm | |
| IL277847A (en) | Modulators of EZH2 expression | |
| IL263577A (en) | Cutaneous dysparelin for the treatment of dysparelinopathy | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| ZA202102271B (en) | Use of cftr modulators for treating cerebrovascular conditions | |
| ZA201906319B (en) | Methods of treating depression | |
| IL274084A (en) | Comb for the treatment of dandruff | |
| IL263468A (en) | New molecules to treat inflammation | |
| IL282365A (en) | TLR9 modulators for cancer therapy | |
| ZA201906542B (en) | Process for the treatment of wastewater | |
| AU2017904820A0 (en) | Methods of treating proliferative disorders |